Annexon Newsroom

BofA Securities Maintains Annexon(ANNX.US) With Buy Rating, Maintains Target Price $12

Moomoo NewsJan 15 05:35 ET · Ratings

Analysts' Top Healthcare Picks: Annexon Biosciences (ANNX), Immunovant (IMVT)

TipRanksJan 15 05:10 ET · Ratings

Annexon Announces 2025 Outlook, ANX005 Targets Guillain-Barré Syndrome BLA In H1 2025, ANX007 Completes Phase 3 Enrollment For Geographic Atrophy In H2 2025, ANX1502 Seeks Clinical Data In Q1 2025; Cash Runway Extends To H2 2026

BenzingaJan 13 08:46 ET

Express News | Annexon Provides 2025 Outlook With Strong Momentum Accelerating Into Breakthrough Year

ReutersJan 13 08:00 ET

Press Release: Annexon Provides 2025 Outlook With Strong Momentum Accelerating Into Breakthrough Year

Dow JonesJan 13 08:00 ET

Annexon Biosciences Strengthens Board for Strategic Growth

TipRanksJan 10 08:35 ET

Express News | Annexon Expands Board of Directors With Appointment of Commercial Executive William “Bj” Jones

ReutersJan 10 08:00 ET

Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswireJan 7 08:00 ET

A Quick Look at Today's Ratings for Annexon(ANNX.US), With a Forecast Between $12 to $30

Moomoo NewsDec 17, 2024 08:00 ET · Ratings

Annexon Biosciences' ANX005: Strong Buy Rating Backed by Promising Efficacy and Sales Potential

TipRanksDec 16, 2024 14:25 ET · Ratings

Annexon, Inc. Reports Positive Real-World Evidence Study Results Supporting ANX005 for Guillain-Barré Syndrome Treatment

Quiver QuantitativeDec 16, 2024 07:41 ET

Annexon Announced Topline Results From A Real-world Evidence Study Supporting Anx005 As A Potential Treatment For Guillain-barré Syndrome

BenzingaDec 16, 2024 07:33 ET

Express News | Annexon Announces Positive Topline Results From Real-World Evidence Study Comparing Anx005 Treatment to Intravenous Immunoglobulin (Ivig) or Plasma Exchange (Pe) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (Gbs)

ReutersDec 16, 2024 07:30 ET

Annexon Insider Buyers Pleased With US$571k Return On Investment

Simply Wall StDec 13, 2024 05:06 ET

Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors With ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting

GlobeNewswireDec 5, 2024 08:00 ET

Analysts Are Bullish on These Healthcare Stocks: Annexon Biosciences (ANNX), Mirum Pharmaceuticals (MIRM)

TipRanksNov 21, 2024 07:11 ET · Ratings

Express News | Annexon Inc : JP Morgan Cuts Target Price to $9 From $11

ReutersNov 20, 2024 00:28 ET

Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswireNov 15, 2024 16:59 ET

Express News | Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

ReutersNov 15, 2024 16:59 ET

Express News | Cantor Fitzgerald Reiterates Overweight on Annexon

BenzingaNov 15, 2024 09:56 ET